AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14736583 — intervention group
Group type: EXPERIMENTAL
Intervention: e-diaries administered via home visits (n=30)
Number of subjects: 60
Study 14736583 — intervention group
Group type: COMPARATOR
Intervention: p-diaries handed out during clinic visits for return by mail (n=30)
Number of subjects: 60
Study 14736583 — intervention group
Group type: EXPERIMENTAL
Intervention: e-diaries
Number of subjects: 60
Study 12610173 — intervention group
Group type: EXPERIMENTAL
Intervention: FRALLE‐93 protocol
Number of subjects: 177
Study 12610173 — intervention group
Group type: COMPARATOR
Intervention: LALA‐94 protocol
Number of subjects: 177
Study 12610173 — intervention group
Group type: EXPERIMENTAL
Intervention: FRALLE‐93 protocol (B-lineage ALL)
Number of subjects: 177
Study 12610173 — intervention group
Group type: COMPARATOR
Intervention: LALA‐94 protocol (B-lineage ALL)
Number of subjects: 177
Study 12610173 — intervention group
Group type: EXPERIMENTAL
Intervention: FRALLE‐93 protocol (T-lineage ALL)
Number of subjects: 177
Study 10577813 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment with ventilation tubes
Number of subjects: 0
Study 8597505 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (5-Fluorouracil and cisplatin)
Number of subjects: 120
Study 8597505 — intervention group
Group type: COMPARATOR
Intervention: Control group (no chemotherapy)
Number of subjects: 120
Study 1936647 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusin restorations in butt-joint preparations
Number of subjects: 94
Study 1936647 — intervention group
Group type: COMPARATOR
Intervention: Occlusin restorations in bevel-edged preparations
Number of subjects: 94
Study 1936647 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-sized Class II restorations in molar teeth
Number of subjects: 94
Study 1936647 — intervention group
Group type: EXPERIMENTAL
Intervention: Class I restorations
Number of subjects: 94
Study 7062298 — intervention group
Group type: EXPERIMENTAL
Intervention: Low GHQ scores
Number of subjects: 320
Study 7062298 — intervention group
Group type: EXPERIMENTAL
Intervention: High GHQ scores
Number of subjects: 320
Study 7062298 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium GHQ scores
Number of subjects: 320
Study 31270846 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES (neuromuscular external electrical stimulation device)
Number of subjects: 0
Study 31270846 — intervention group
Group type: COMPARATOR
Intervention: Comparator device (iTouch sure)
Number of subjects: 0
Study 31270846 — intervention group
Group type: EXPERIMENTAL
Intervention: Both NMES and comparator device
Number of subjects: 0
Study 31270846 — intervention group
Group type: COMPARATOR
Intervention: Comparator device
Number of subjects: 0
Study 31270846 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES
Number of subjects: 0
Study 27500896 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial glycolic acid (GA) peel every 3 weeks with twice daily 20% azelaic acid (AA) cream
Number of subjects: 60
Study 27500896 — intervention group
Group type: COMPARATOR
Intervention: 20% azelaic acid (AA) cream
Number of subjects: 60
Study 26763917 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg triflusal twice a day
Number of subjects: 1080
Study 26763917 — intervention group
Group type: COMPARATOR
Intervention: 75 mg clopidogrel once daily
Number of subjects: 1080
Study 26763917 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 1080
Study 24240777 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment aimed at lowering systolic blood pressure by 10% to 25% within the first 24 hours, achieving blood pressure less than 140/90 mm Hg within 7 days, and maintaining this level during hospitalization.
Number of subjects: 4071
Study 24240777 — intervention group
Group type: COMPARATOR
Intervention: Control group (discontinued all antihypertensive medications during hospitalization).
Number of subjects: 4071
Study 24240777 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment group.
Number of subjects: 4071
Study 24240777 — intervention group
Group type: COMPARATOR
Intervention: Control group.
Number of subjects: 4071
Study 22093005 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit/Vegetable (FV) juice powder concentrates
Number of subjects: 60
Study 22093005 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit/Vegetable/Berry (FVB) juice powder concentrates
Number of subjects: 60
Study 22093005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 18562427 — intervention group
Group type: EXPERIMENTAL
Intervention: alprazolam 1 mg
Number of subjects: 12
Study 18562427 — intervention group
Group type: EXPERIMENTAL
Intervention: zolpidem 5 mg
Number of subjects: 12
Study 18562427 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 17155987 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine extended-release (ER)
Number of subjects: 0
Study 17155987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15619403 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpolymeric paclitaxel-coated stents
Number of subjects: 0
Study 15619403 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents
Number of subjects: 0
Study 12477009 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group informed of the blue team's aggressive reputation
Number of subjects: 38
Study 12477009 — intervention group
Group type: COMPARATOR
Intervention: Control group not informed of the blue team's aggressive reputation
Number of subjects: 38
Study 9163287 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with connective tissue disease (EUCTD, rheumatoid arthritis, lupus, polymyositis)
Number of subjects: 453
Study 9163287 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with connective tissue disease (EUCTD, rheumatoid arthritis, lupus)
Number of subjects: 453
Study 9163287 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with connective tissue disease
Number of subjects: 453
Study 9163287 — intervention group
Group type: COMPARATOR
Intervention: Control group (blood donors and patients with known vasculitis)
Number of subjects: 453
Study 8424580 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent suction and pressure treatment
Number of subjects: 34
Study 8424580 — intervention group
Group type: COMPARATOR
Intervention: Placebo applications
Number of subjects: 34
Study 3315536 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine 50 mg once a day
Number of subjects: 128
Study 3315536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 31751317 — intervention group
Group type: EXPERIMENTAL
Intervention: FMT capsules from a donor enriched in Lachnospiraceae and Ruminococcaceae
Number of subjects: 20
Study 31751317 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 20
Study 27473187 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2R1 genetic polymorphisms (rs1562902 and rs10741657 SNPs)
Number of subjects: 218
Study 27473187 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2R1 genetic polymorphisms (rs10766197 and rs12794714 SNPs)
Number of subjects: 218
Study 27473187 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D3 supplementation (600 IU daily or 3750 IU daily)
Number of subjects: 218
Study 29509347 — intervention group
Group type: EXPERIMENTAL
Intervention: Quad-helix appliance
Number of subjects: 40
Study 29509347 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 40
Study 24576844 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil-based parenteral lipid preparation (FOLP) at 1.5 g/kg/day
Number of subjects: 16
Study 24576844 — intervention group
Group type: COMPARATOR
Intervention: Soy-based parenteral lipid preparation (SLP) at 1.5 g/kg/day
Number of subjects: 16
Study 24576844 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil-based parenteral lipid preparation (FOLP)
Number of subjects: 16
Study 22682229 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined universal and targeted program (Toddlers Without Tears group parenting program followed by Family Check‐Up one‐on‐one program)
Number of subjects: 0
Study 22682229 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted Family Check‐Up program
Number of subjects: 0
Study 22682229 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 19448211 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (n = 64) via ACD (end‐tidal 0.5‐1 vol%)
Number of subjects: 125
Study 19448211 — intervention group
Group type: COMPARATOR
Intervention: Propofol (n = 61)
Number of subjects: 125
Study 17617556 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS
Number of subjects: 25
Study 17617556 — intervention group
Group type: EXPERIMENTAL
Intervention: NFSC
Number of subjects: 25
Study 17617556 — intervention group
Group type: EXPERIMENTAL
Intervention: AUC A
Number of subjects: 25
Study 17617556 — intervention group
Group type: EXPERIMENTAL
Intervention: AUC B
Number of subjects: 25
Study 15102335 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam (1 mg)
Number of subjects: 15
Study 15102335 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg)
Number of subjects: 15
Study 11248812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 346
Study 9568728 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha (150 IU)
Number of subjects: 60
Study 9568728 — intervention group
Group type: COMPARATOR
Intervention: Sucralfate (250 mg)
Number of subjects: 60
Study 8142151 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (CT) alone (arm I: 26 patients)
Number of subjects: 80
Study 8142151 — intervention group
Group type: EXPERIMENTAL
Intervention: CT combined with IFN‐gamma (arm II: 27 patients)
Number of subjects: 80
Study 8142151 — intervention group
Group type: EXPERIMENTAL
Intervention: CT combined with both IFN‐gamma and IFN‐alpha (arm III: 27 patients)
Number of subjects: 80
Study 8142151 — intervention group
Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 80
Study 3060424 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole 500 mg vaginal tablet once a month
Number of subjects: 85
Study 3060424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 3060424 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole 500 mg vaginal tablet once a month (after relapse)
Number of subjects: 85
Study 3060424 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole 500 mg vaginal tablet twice a month
Number of subjects: 85
Study 1360087 — intervention group
Group type: EXPERIMENTAL
Intervention: Early administration of Exosurf (synthetic surfactant)
Number of subjects: 2690
Study 1360087 — intervention group
Group type: COMPARATOR
Intervention: Delayed selective administration of Exosurf (synthetic surfactant)
Number of subjects: 2690
Study 1360087 — intervention group
Group type: EXPERIMENTAL
Intervention: Up-to-four doses of surfactant (if signs of RDS persisted or recurred)
Number of subjects: 2690
Study 1360087 — intervention group
Group type: COMPARATOR
Intervention: Two doses of surfactant 12 hours apart
Number of subjects: 2690
Study 692138 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant treatment (chemotherapy, radiotherapy, immunotherapy)
Number of subjects: 0
Study 692138 — intervention group
Group type: COMPARATOR
Intervention: Curative resection
Number of subjects: 0
Study 31818089 — intervention group
Group type: EXPERIMENTAL
Intervention: Orogastric tube guide (GTG)
Number of subjects: 151
Study 31818089 — intervention group
Group type: COMPARATOR
Intervention: Conventional 'blind' technique (CONV)
Number of subjects: 151
Study 29923748 — intervention group
Group type: EXPERIMENTAL
Intervention: Values intervention (n = 18)
Number of subjects: 32
Study 29923748 — intervention group
Group type: COMPARATOR
Intervention: Control condition (n = 14)
Number of subjects: 32
Study 28857772 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline
Number of subjects: 292
Study 28857772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study 24814382 — intervention group
Group type: EXPERIMENTAL
Intervention: Prudent low-fat breakfast (PB) based on Nordic foods provided ad libitum
Number of subjects: 79
Study 24814382 — intervention group
Group type: COMPARATOR
Intervention: Usual breakfast (Control)
Number of subjects: 79
Study 23506397 — intervention group
Group type: EXPERIMENTAL
Intervention: MAPS intervention (HE + up to 18 MAPS counseling calls over 18 months)
Number of subjects: 400
Study 23506397 — intervention group
Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 400
Study 21356006 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% green tea rinse for 5 minutes
Number of subjects: 25
Study 19220164 — intervention group
Group type: EXPERIMENTAL
Intervention: New formulation of azelastine nasal spray
Number of subjects: 862
Study 19220164 — intervention group
Group type: COMPARATOR
Intervention: Original formulation of azelastine nasal spray
Number of subjects: 862
Study 16618912 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature-controlled radiofrequency tonsil reduction and adenoidectomy (TCRF&A)
Number of subjects: 23
Study 16618912 — intervention group
Group type: COMPARATOR
Intervention: Conventional tonsillectomy and adenoidectomy (T&A)
Number of subjects: 23
Study 15531313 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Anesthesia (TA)
Number of subjects: 306
Study 15531313 — intervention group
Group type: COMPARATOR
Intervention: Retrobulbar Anesthesia (RA)
Number of subjects: 306
Study 11712341 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.1 mg
Number of subjects: 50
Study 11712341 — intervention group
Group type: COMPARATOR
Intervention: Control (no morphine)
Number of subjects: 50
Study 9152099 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous low dose (2.5‐10 mg every 2 weeks)
Number of subjects: 313
Study 9152099 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted, early intervention (fluphenazine only when symptomatic)
Number of subjects: 313
Study 9152099 — intervention group
Group type: COMPARATOR
Intervention: Continuous moderate dose (standard) (12.5‐50 mg every 2 weeks)
Number of subjects: 313
Study 8424849 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg SDZ ENA 713
Number of subjects: 20
Study 8424849 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg SDZ ENA 713
Number of subjects: 20
Study 8424849 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.3 mg SDZ ENA 713
Number of subjects: 20
Study 8424849 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg SDZ ENA 713
Number of subjects: 20
Study 8424849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3306291 — intervention group
Group type: EXPERIMENTAL
Intervention: Org OD 14 (2.5 mg/day, per os)
Number of subjects: 124
Study 3306291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 3306291 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 124
Study 3306291 — intervention group
Group type: EXPERIMENTAL
Intervention: Org OD 14
Number of subjects: 124
Study 31628001 — intervention group
Group type: EXPERIMENTAL
Intervention: Unplanned landings
Number of subjects: 20
Study 30777015 — intervention group
Group type: COMPARATOR
Intervention: Conventional group (algorithm based on conventional coagulation assays: platelet count, aPTT, PT, fibrinogen)
Number of subjects: 26
Study 30777015 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care (PoC) group (monitoring using activated rotational thromboelastometry (ROTEM®) combined with multiple aggregometry (Multiplate®))
Number of subjects: 26
Study 30777015 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Conventional and PoC)
Number of subjects: 26
Study 30777015 — intervention group
Group type: EXPERIMENTAL
Intervention: PoC group only
Number of subjects: 26
Study 27339124 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine PAI
Number of subjects: 119
Study 27339124 — intervention group
Group type: COMPARATOR
Intervention: Morphine spinal anesthesia
Number of subjects: 119
Study 27339124 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine PAI
Number of subjects: 119
Study 27339124 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal morphine
Number of subjects: 119
Study 25821098 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of proton pump inhibitor (PPI)
Number of subjects: 273
Study 25821098 — intervention group
Group type: COMPARATOR
Intervention: Bolus injection of proton pump inhibitor (PPI)
Number of subjects: 273
Study 23307404 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO-PRO (0.8 g sucrose · kg‐1 · hr‐1 with 0.3 g · kg‐1 · hr‐1 whey-protein isolate)
Number of subjects: 0
Study 23307404 — intervention group
Group type: COMPARATOR
Intervention: CHO (0.8 g sucrose · kg‐1 · hr‐1)
Number of subjects: 0
Study 23307404 — intervention group
Group type: COMPARATOR
Intervention: CHO-CHO (1.1 g sucrose · kg‐1 · hr‐1)
Number of subjects: 0
Study 23307404 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO-PRO
Number of subjects: 0
Study 23307404 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 0
Study 20805294 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan 62.5 mg twice daily for 4 weeks and 125 mg twice daily thereafter for 20 weeks (n=98)
Number of subjects: 188
Study 20805294 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=90)
Number of subjects: 188
Study 18077611 — intervention group
Group type: EXPERIMENTAL
Intervention: Refrigerated formulation of Zostavax (n = 182)
Number of subjects: 367
Study 18077611 — intervention group
Group type: COMPARATOR
Intervention: Frozen formulation of Zostavax (n = 185)
Number of subjects: 367
Study 16162683 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Enteral Nutrition (PEN)
Number of subjects: 50
Study 16162683 — intervention group
Group type: COMPARATOR
Intervention: Total Enteral Nutrition (TEN)
Number of subjects: 50
Study 11895877 — intervention group
Group type: EXPERIMENTAL
Intervention: 81 mg aspirin
Number of subjects: 60
Study 11895877 — intervention group
Group type: EXPERIMENTAL
Intervention: 325 mg aspirin
Number of subjects: 60
Study 11895877 — intervention group
Group type: EXPERIMENTAL
Intervention: 650 mg aspirin
Number of subjects: 60
Study 11895877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 10197490 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy (Ethanolamine oleate)
Number of subjects: 43
Study 10197490 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 43
Study 7549381 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% Cantharides extract
Number of subjects: 50
Study 2249379 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg codeine
Number of subjects: 24
Study 2249379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 6108299 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of lorazepam
Number of subjects: 20
Study 6108299 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of oxazepam
Number of subjects: 20
Study 6108299 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of temazepam
Number of subjects: 20
Study 29033116 — intervention group
Group type: EXPERIMENTAL
Intervention: Accurate norms information (experimental group)
Number of subjects: 68
Study 29033116 — intervention group
Group type: COMPARATOR
Intervention: Fun facts (control group)
Number of subjects: 68
Study 26996542 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated bihormonal artificial pancreas
Number of subjects: 10
Study 26996542 — intervention group
Group type: COMPARATOR
Intervention: Control (insulin pump therapy)
Number of subjects: 10
Study 24614112 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (500 mg, three times a day)
Number of subjects: 92
Study 24614112 — intervention group
Group type: COMPARATOR
Intervention: Cellulose (placebo, 500 mg, three times a day)
Number of subjects: 92
Study 22587593 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD-alum
Number of subjects: 70
Study 22587593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 20626364 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine-enriched enteral nutrition
Number of subjects: 72
Study 20626364 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 72
Study 17903568 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 60
Study 17903568 — intervention group
Group type: COMPARATOR
Intervention: Hydrocodone with acetaminophen
Number of subjects: 60
Study 16243052 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetition of printed words with varying word frequency and case alternation
Number of subjects: 0
Study 16243052 — intervention group
Group type: COMPARATOR
Intervention: Lexical decision task (LD)
Number of subjects: 0
Study 16243052 — intervention group
Group type: COMPARATOR
Intervention: Naming task (NAM)
Number of subjects: 0
Study 12234038 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 813
Study 12234038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 813
Study 10422530 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased luminance
Number of subjects: 0
Study 10422530 — intervention group
Group type: COMPARATOR
Intervention: Feedback about low light levels
Number of subjects: 0
Study 8525411 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal scrubbing with 10% povidone‐iodine immediately prior to the operation (Group II)
Number of subjects: 30
Study 8525411 — intervention group
Group type: COMPARATOR
Intervention: Routine vaginal scrubbing followed by abdominal scrubbing (Group I)
Number of subjects: 30
Study 2147833 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone (1 mg/kg by rapid intravenous injection every 8 hours for 48 hours)
Number of subjects: 44
Study 2147833 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (furosemide, nitrates, dopamine‐dobutamine)
Number of subjects: 44
Study 2147833 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone
Number of subjects: 44
Study 2147833 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 44
Study 6994771 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine 2.0 mg
Number of subjects: 22
Study 6994771 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine 1.0 mg
Number of subjects: 22
Study 6994771 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.15 mg
Number of subjects: 22